Search results
11 cze 2024 · On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of...
17 lip 2023 · Full results about the Alzheimer's disease drug donanemab have been released today, supporting earlier trial results that suggested the breakthrough drug may slow down the progression of the disease.
2 lip 2024 · The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
29 lis 2022 · We conducted an 18-month, multicenter, double-blind, phase 3 trial involving persons 50 to 90 years of age with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to ...
17 lip 2023 · Promising preliminary results from a trial of the Alzheimer’s drug donanemab, first announced in May, have now been confirmed. The full results were made public today at the Alzheimer’s Association International Conference by the pharmaceutical company Eli Lilly, which manufactures the drug.
4 maj 2023 · Alzheimer’s drug donanemab: what promising trial means for treatments. Results suggest that the amyloid-targeting drug candidate slows cognitive decline in some people, but questions remain...
24 lip 2023 · The Food and Drug Administration (FDA) recently granted full approval to a new Alzheimer’s treatment called lecanemab, which has been shown to moderately slow cognitive and functional decline in early-stage cases of the disease.
